Dr. Perl discusses results from the phase I CHRYSALIS trial, which investigated gilteritinitib in patients with relapsed/refractory acute myeloid leukemia.
Alexander Perl, MD: The New FLT3 Inhibitor Gilteritinib is “Well-Tolerated” in AML
Recent Articles
Can a Virtual Benign Hematology Consult Improve Access to and Quality of Care?
A multidisciplinary team of researchers developed a virtual benign hematology consultative service that can potentially reduce the time it takes a specialist to examine...
Hospitals Struggling to Break Even on CAR T-Cell Therapy
Since the first chimeric antigen receptor (CAR) T-cell therapies were approved by the U.S. Food and Drug Administration (FDA) in 2017, U.S. hospitals have...
Proposed 2020 Budget Would Slash Cancer Funding
On March 11, President Donald Trump released his proposed fiscal year 2020 budget, which included a 12-percent cut to the U.S. Department of Health...
UnitedHealth Will Redirect Drug Rebates to Consumers
UnitedHealth, one of the largest insurers in the U.S., announced that all of its new employer-sponsored insurance plans in 2020 will take the drug...
Are E-Consults the Future of Health Care?
More health-care workplaces are experimenting with electronic consultation, or e-consult, services, which may save time and money for patients and providers.
e-Consults allow primary-care providers...
Current Issue
March 2019, Volume 5, Issue 4
This issue features a look at the misconceptions about travel-associated blood clots, the treatment of young patients with myeloma, and more.
